Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s.
In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm, who will lead development and commercialisation in China.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @proactive_UK: $STX Shield Therapeutics says TEVA has withdrawn patent challenge https://t.co/r95T9CVRYJ via @proactive_UK @shieldTx #S…
RT @VOXmarkets: Shield Therapeutics - Withdrawal of all oppositions by TEVA #STX @ShieldTx https://t.co/Y5ToetaXcw #voxmarkets #investing #…
RT @ruth_proactive: $STX Shield Therapeutics encouraged by US interest in iron deficiency treatment https://t.co/66I7TkK2NW via @proactive_…
